India's Pioglitazone Fiasco Reignites Criticism Of Regulatory Process
This article was originally published in PharmAsia News
Executive Summary
India's recent ban on pioglitazone based on physician complaints and then an about-face allowing the drug back has reignited debates about the nation's process for deciding on drug safety.